NCT05017649

Role of A2A Receptor in Hypercholesterolemic Patients

Characterization of Adenosine A2A Receptor Expression and Fubnction in Hypercholesterolemic Patients

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: Assistance Publique Hopitaux De Marseille · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

Hypercholesterolemia promotes chronic inflammation, endothelial dysfunction, atherosclerosis and is a major risk factor for cardiovascular disease (CVD). Treatment with lipid-lowering drugs (statins, ezetimibe, PCSK9 inhibitors or LDL-apheresis) reduces the risk of major cardiovascular events in proportion to the absolute reduction of LDL-cholesterol (LDL-C). Nevertheless, a better understanding of the effects of hypercholesterolemia on the cardiovascular and immune systems could help identify all the mechanisms responsible for the excess risk of CVD in hypercholesterolemic patients and develop better prevention and treatment strategies. Adenosine via A2A receptors (A2AR) plays a crucial role in the regulation of the cardiovascular and immune systems. In this project, the investigators wish : * To study whether the expression and function of A2AR in PBMCs are altered in human hypercholesterolemia, using as a study model a larger cohort of patients with hypercholesterolemia of increasing level and severity: polygenic form, heterozygous genetic form and homozygous genetic form in comparison with healthy subjects with normal cholesterol levels. * To study whether A2AR expression and function in PBMCs are associated with blood levels of LDL-C and homocysteine and with the inflammatory status of patients. * To assess whether the cholesterol-lowering therapies currently used to reduce LDL-C levels and thus the risk of CVD in hypercholesterolemic patients have an impact on possible alterations of A2AR expression and function in PBMCs.

Conditions

• Hypercholesterolemia

Interventions

Type	Name	Description
BIOLOGICAL	Blood sample	Blood sampling.

Timeline

• Start date: 2021-09-20
• Primary completion: 2026-03-19
• Completion: 2026-06-19
• First posted: 2021-08-24
• Last updated: 2023-07-27

Locations

1 site across 1 country: France